Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

por Brada, M, Judson, I, Beale, P, Moore, S, Reidenberg, P, Statkevich, P, Dugan, M, Batra, V, Cutler, D
Publicado 1999

Marked inactivation of O(6)-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

por Tolcher, A W, Gerson, S L, Denis, L, Geyer, C, Hammond, L A, Patnaik, A, Goetz, A D, Schwartz, G, Edwards, T, Reyderman, L, Statkevich, P, Cutler, D L, Rowinsky, E K
Publicado 2003

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.

por Estlin, E. J., Lashford, L., Ablett, S., Price, L., Gowing, R., Gholkar, A., Kohler, J., Lewis, I. J., Morland, B., Pinkerton, C. R., Stevens, M. C., Mott, M., Stevens, R., Newell, D. R., Walker, D., Dicks-Mireaux, C., McDowell, H., Reidenberg, P., Statkevich, P., Marco, A., Batra, V., Dugan, M., Pearson, A. D.
Publicado 1998